Abstract 2706: Inhibition of PFKFB3/glycolysis overcomes chemoresistance in ovarian cancers
Susmita Mondal(Diamond Harbour Women's University), Viji Shridhar(Mayo Clinic in Arizona), Eleftheria Kalogera(Mayo Clinic), Jason Chesney(University of Louisville Hospital), Debarshi Roy, Gilles Tapolsky(Advanced Cancer Therapeutics), Sucheta Telang(University of Louisville), Ashwani Khurana(Mayo Clinic in Arizona)
Cited by 1
Related Papers
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|398
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
|PubMed|2002|326
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
|Journal for ImmunoTherapy of Cancer|2022|305
Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer
|Journal of Biological Chemistry|2003|248